Summary
70% of medicines given to children have never been studied in pediatric populations. Children who need treatments represent a relatively small population. This alone presents unique challenges for pediatric drug development. Since the 1990s, authorities around the world have worked to solve these issues, enacting legislations to encourage pediatric drug development plans—but there is still more to do. This two-part paper discusses the role global collaboration will play in bringing life-changing drugs to children who need them most. Download to read Part Two or click here to read Part One.
Register to download
Global Pediatric Drug Development Collaboration Part Two
You may also be interested in:
White Paper
The Impact Of Contraceptive Requirements On Pediatric Clinical Trials
Contraceptive requirements applied to women of child-bearing potential participating in clinical trials also apply to children participating in…
Blog
The RACE for Children Act
In the US, legislation such as the Better Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) have helped to…
Blog
What Does the Future of Childhood Cancer Treatment Look Like?
Now that the RACE for Children Act has come into effect, the drug development industry and patients and their families are optimistic—more drugs will…